The characteristics of quality of life impairment in adult growth hormone (GH)-deficient survivors of cancer and their response to GH replacement therapy.

What Was Tested

This clinical trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

All GHD patients were considered for GH replacement on the basis of subjectively poor quality of life (QOL).

Primary outcome measures were scores of QOL instruments psychological general well-being schedule (PGWB) and assessment of GH deficiency in adults (AGHDA) at baseline and early (6-13 months) and long-term (24-77 months) treatment follow-up.

Who Took Part

The abstract describes 27 women taking part.

The age groups tagged for this paper are teenagers, adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

These variables were included in all fitted models.

What Was Measured

Primary outcome measures were scores of QOL instruments psychological general well-being schedule (PGWB) and assessment of GH deficiency in adults (AGHDA) at baseline and early (6-13 months) and long-term (24-77 months) treatment follow-up.

Of secondary interest were six PGWB domains.

The subject headings attached to it are Adenoma, Brain Neoplasms, Cohort Studies, Human Growth Hormone, Insulin-Like Growth Factor I, Pituitary Neoplasms and Prolactinoma.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 27 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2005 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.